Results 81 to 90 of about 7,552 (172)

Rational Design of Multifunctional Tacrine Derivatives as Candidates for the Treatment of Alzheimer and Parkinson Diseases

ChemMedChem, Volume 21, Issue 15, 14 August 2026.
We present a set of multifunctional tacrine derivatives, designed with the CADMA‐Chem protocol, aimed for Alzheimer and Parkinson diseases. Of the tacrines designed, TAC‐674 and TAC‐678 are the best candidates to act as multifunctional antioxidants and neuroprotectors for Alzheimer and Parkinson diseases, respectively.
Eugenia Dzib, Luis Felipe Hernández‐Ayala, Silvana Silva‐Aguirre, Annia Galano   +3 more
wiley   +1 more source

Drug‐induced cholestasis

Hepatology Communications, 2017
Cholestatic drug‐induced liver injury (DILI) can be a diagnostic challenge due to a large differential diagnosis, variability in clinical presentation, and lack of serologic biomarkers associated with this condition.
Vinay Sundaram, Einar S. Björnsson
doaj   +1 more source

Mechanistic insights into antiretroviral drug‐induced liver injury

Pharmacology Research & Perspectives, 2020
All classes of antiretroviral therapy (ART) have been implicated to induce adverse drug reactions such drug‐induced liver injury (DILI) and immune‐mediated adverse reactions in Human Immunodeficiency Virus (HIV) infected individuals.
Jamie N. Pillaye, Mohlopheni J. Marakalala, Nonhlanhla Khumalo, Wendy Spearman, Hlumani Ndlovu   +4 more
doaj   +1 more source

Adverse events in bedaquiline‐ and pretomanid‐based regimens for drug‐resistant tuberculosis from trial, implementation and pharmacovigilance studies

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2607-2623, August 2026.
Abstract The availability of safety data, particularly concerning adverse events (AEs) associated with the new shorter regimen for drug‐resistant tuberculosis (TB) containing a bedaquiline–pretomanid‐based regimen, is still limited. This systematic review aims to provide a comprehensive and updated analysis of AEs related to this new regimen by ...
Nisa Maria, Annisa Lazuardi Larasati, Indri Yuliani Hamdani, Jin‐Gun Cho, Jan‐Willem C. Alffenaar   +4 more
wiley   +1 more source

Disulfiram‐Induced Hepatotoxicity in a Patient With Alcohol Use Disorder: A Case Report

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Disulfiram can cause severe and potentially fatal hepatotoxicity, particularly in patients with preexisting liver disease. In Bhutan, where alcohol‐related liver disease represents a major public health burden and pharmacological options for relapse prevention remain limited, careful patient selection, hepatic assessment, and early monitoring ...
Sonam Wangchuk, Bikram Chhetri, Jiann Lin Loo   +2 more
wiley   +1 more source

Integrative GC–MS, FT‐IR, and Molecular Docking Analysis of Drimycarpus racemosus (Roxb.) Hook.f ex Marchand: In Vivo Analgesic and Antidiabetic Potential

Food Science &Nutrition, Volume 14, Issue 8, August 2026.
GC–MS profiling of D. racemosus identified bioactive phytochemicals with promising molecular interactions through docking analysis. The methanolic extract demonstrated significant antinociceptive activity against acetic acid‐ and formalin‐induced pain and exhibited antidiabetic effects in streptozotocin‐induced diabetic Swiss albino mice, supporting ...
Md Sajib Ali, Md. Rakibul Islam, M. A. Rafi, Sanjana Haque Esha, Md. Mehedi Hasan, Payar Hossain, Abdullah Ripon, Nilufar Sultana   +7 more
wiley   +1 more source

3D Liver Fibrosis Models in Lab: A Novel Modality for Drug Screening

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Liver fibrosis is the common consequence of liver injury caused by a variety of chronic liver disorders. This condition leads to the development of more severe complications, particularly cirrhosis and hepatocellular carcinoma. Despite abundant studies, the fundamental cell and molecular mechanisms of liver fibrosis are still unknown.
Hani Keshavarz Alikhani, Fatemeh Majidi, Mahsa Ghasemzad, Anastasia Shpichka, Anastasia Nestorova, Zahra Hendi, Elham Rismani, Daria Kuznetsova, Peter Timashev, Massoud Vosough, Abbas Piryaei   +10 more
wiley   +1 more source

Role of Gut Microecology in the Pathogenesis of Drug-Induced Liver Injury and Emerging Therapeutic Strategies

Molecules
Drug-induced liver injury (DILI) is a common clinical pharmacogenic disease. In the United States and Europe, DILI is the most common cause of acute liver failure.
Yuqiao Huang, Yu Zhang, Kaireng Wu, Xinxin Tan, Tian Lan, Guixiang Wang   +5 more
doaj   +1 more source

Emerging Immune‐Based Therapeutic Strategies in Hepatocellular Carcinoma

Liver International, Volume 46, Issue 8, August 2026.
ABSTRACT Hepatocellular carcinoma (HCC) remains a leading cause of cancer‐related mortality worldwide despite recent advances in systemic therapy. The introduction of immune checkpoint inhibitors has substantially expanded treatment options for advanced disease; however, durable responses are observed only in a subset of patients.
Janine Kah, Werner Dammermann, Stefan Lueth   +2 more
wiley   +1 more source

The role of endoplasmic reticulum aminopeptidase ERAP2 pathogenic mutation rs1363907 in amoxicillin clavulanate-induced liver injury: a special case report

Frontiers in Pharmacology
Idiosyncratic hepatotoxicity is a type of drug-induced liver injury (DILI) that is unpredictable and clinically severe, and amoxicillin clavulanate (AC) is the most implicated drug in DILI worldwide. The clinical manifestations of amoxicillin clavulanate-
Yan Zhan, Yan Zhan, Yan Zhan, Yan Zhan, Jin-Mao Liao, Ling Ye, Ling Ye, Ling Ye, Ling Ye, Long Zhang, Long Zhang, Long Zhang, Long Zhang, Long Zhang, Zheng Zhang, Ji-Ye Yin, Ji-Ye Yin, Ji-Ye Yin, Ji-Ye Yin   +18 more
doaj   +1 more source